I agree that this site is using cookies. You can find further informations here.
X
Lamanna, Nicole
147  results:
Search for persons X
?
1

Pirtobrutinib, a highly selective, non-covalent (reversible..:

Wierda, William G ; Shah, Nirav N ; Cheah, Chan Y...
The Lancet Haematology.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

Fixed-Duration Pirtobrutinib plus Venetoclax with or withou..:

Roeker, Lindsey Elizabeth ; Woyach, Jennifer A. ; Cheah, Chan Yoon Y...
Blood Journal.  , 2024
Link: https://doi.org/10.1182/..
 
?
3

Characterization of zanubrutinib safety and tolerability pr..:

Brown, Jennifer R. ; Ghia, Paolo ; Jurczak, Wojciech...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
4

Similar efficacy of ibrutinib arms across ALPINE and ELEVAT..:

Shadman, Mazyar ; Tedeschi, Alessandra ; Mohseninejad, Leyla...
Blood Cancer Journal.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
5

Plain language summary of zanubrutinib or ibrutinib in chro..:

Brown, Jennifer R ; Eichhorst, Barbara ; Hillmen, Peter...
Future Oncology.  20 (2024)  12 - p. 717-726 , 2024
Link: https://doi.org/10.2217/..
 
?
6

Treatment Discontinuation Patterns for Patients With Chroni..:

Shadman, Mazyar ; Manzoor, Beenish S. ; Sail, Kavita...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  7 - p. 515-526 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Health-related quality of life outcomes associated with zan..:

Tam, Constantine S. ; Lamanna, Nicole ; O'Brien, Susan M....
Current Medical Research and Opinion.  39 (2023)  11 - p. 1497-1503 , 2023
Link: https://doi.org/10.1080/..
 
?
8

POSTER: CLL-542 High Rates of Undetectable Minimal Residual..:

Lipsky, Andrew ; Hill, Brian ; Winter, Allison...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S173 , 2023
Link: https://doi.org/10.1016/..
 
?
9

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRO..:

Eichhorst, Barbara ; Lamanna, Nicole ; O'brien, Susan...
HemaSphere.  7 (2023)  S3 - p. e02428b9 , 2023
Link: https://doi.org/10.1097/..
 
?
10

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS A..:

Rhodes, Joanna ; Shadman, Mazyar ; Lamanna, Nicole...
HemaSphere.  7 (2023)  S3 - p. e96103aa , 2023
Link: https://doi.org/10.1097/..
 
?
11

P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CH..:

Lansigan, Frederick ; A. Eyre, Toby ; Ghosh, Nilanjan...
HemaSphere.  7 (2023)  S3 - p. e6855326 , 2023
Link: https://doi.org/10.1097/..
 
?
12

POSTER: CT-168 Comparison of Bleeding-Related Events in Pat..:

Konig, Heiko ; Tam, Constantine S. ; Lamanna, Nicole...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S229 , 2023
Link: https://doi.org/10.1016/..
 
?
13

EXABS-209-CLL The Case for Extending Treatment in MRD+ Pati..:

Lipsky, Andrew ; Lamanna, Nicole
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S98-S99 , 2023
Link: https://doi.org/10.1016/..
 
?
14

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WH..:

Lamanna, Nicole ; Tam, Constantine ; Jurczak, Wojciech...
HemaSphere.  7 (2023)  S3 - p. e724362f , 2023
Link: https://doi.org/10.1097/..
 
?
15

PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY O..:

Baker, Deborah ; York, Nick ; Huntley, Kathryn...
HemaSphere.  7 (2023)  S3 - p. e027806b , 2023
Link: https://doi.org/10.1097/..
 
1-15